What is HemoSonics?
HemoSonics is a prominent player in the medical device sector, dedicated to developing clinical tools that provide actionable information in critical care settings. Its flagship product, the Quantra® Hemostasis Analyzer, is engineered to enhance patient outcomes and lower medical expenses by offering unique coagulation insights for rapid interpretation and streamlined point-of-care bleeding management. Headquartered in Charlottesville, VA, with R&D and manufacturing in Durham, NC, HemoSonics is an integral part of the Stago group, a leader in in vitro diagnostics with a focus on thrombosis and hemostasis.
How much funding has HemoSonics raised?
HemoSonics has raised a total of $25.9M across 6 funding rounds:
Unspecified
$1M
Unspecified
$1.3M
Private Equity
$3.7M
Private Equity
$4M
Private Equity
$15M
Debt
$1M
Unspecified (2008): $1M, investors not publicly disclosed
Unspecified (2013): $1.3M, investors not publicly disclosed
Private Equity (2014): $3.7M, investors not publicly disclosed
Private Equity (2015): $4M, investors not publicly disclosed
Private Equity (2017): $15M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
What's next for HemoSonics?
The recent major strategic investment signals a new phase of growth and development for HemoSonics. This capital infusion is expected to accelerate the company's market penetration and further refine its Quantra® Hemostasis Analyzer technology. With a clear trajectory supported by consistent backing, HemoSonics is poised to expand its impact on critical care workflows, aiming to solidify its position as a key innovator in hemostasis diagnostics and contribute to more efficient, cost-effective patient management.
See full HemoSonics company page
